US-based medical equipment manufacturer Electromedical Products International (EPI) has acquired medical device firm Pulvinar Neuro, for an undisclosed sum.

Pulvinar is research-oriented medical device firm focused on development of closed-loop and other novel neuromodulating brain stimulation solutions for mental health disorders.

With the acquisition, Pulvinar is enabled to advance the development and commercialisation of its patented technologies, including transcranial alternating current stimulation (tACS).

The company will also improve its individualised feedback stimulation, and cloud-enabled digital therapeutics for psychiatric and neurological illnesses.

In addition, the transaction is expected to advance and expand the company’s collaborations with the research community to develop its technology for clinical applications.

Pulvinar Neuro founder Flavio Frohlich said: “Our transaction with EPI, the leader in non-invasive electric brain stimulation, is a unique opportunity to dramatically accelerate the translation of the next generation brain stimulation technology from the research to the clinical arena.”

Pulvinar Neuro CEO Leah Townsend said: “I am looking forward to working with EPI to bring the next generation of personalized non-invasive brain stimulation to market, complementary with EPI’s suite of devices, which we are confident will benefit millions of patients who are looking for effective and safe treatment options.”

Established in 1981, EPI is engaged in engineering and manufacturing medical devices using cranial electrotherapy stimulation (CES), to treat mental health and pain disorders.

It offers low-current, non-invasive microcurrent electrical therapy (MET) technology for the drug-free treatment of anxiety, insomnia, depression, and pain.

The company has been commercialising its patented, FDA approved Alpha-Stim technology, with operations across more than 50 countries worldwide.

Its products have utility patents in the US, China and Europe and are used in medical facilities, physician offices and at home in the US.

EPI CEO Tracey B Kirsch said: “We are very excited about adding Pulvinar and its team of brain stimulation and data science experts to our team.

“Pulvinar expands our scientific and research capabilities addressing non-invasive, drug free treatment solutions for anxiety, insomnia, depression and pain as well as other indications we plan to pursue for FDA clearance.”